Curated educational summaries and key research references organized by topic, designed to help you understand the scientific context behind CoGenetix's educational content.
Consumer and clinical genetic testing has advanced dramatically, with GWAS studies identifying thousands of loci associated with complex traits. SNP-based panels for wellness applications are grounded in population association studies and are most informative when combined with current biomarker data. Key research areas include nutrigenomics, pharmacogenomics, and polygenic risk score development.
Foundation of common variant association studies; contextualizes the polygenic architecture of health-relevant traits.
Reviews the development, validation, and clinical applicability of polygenic scores for cardiovascular and metabolic conditions.
Evaluates the scientific validity and clinical utility of consumer genetic testing panels.
Comprehensive review of gene-nutrient interactions relevant to precision nutrition applications.
Reviews evidence for MTHFR variant associations with homocysteine, folate status, and health outcomes.
The hallmarks of aging framework has organized longevity science around twelve interconnected biological processes. Interventions targeting telomere maintenance, mitochondrial function, cellular senescence, autophagy, and nutrient sensing pathways show promise in preclinical and early human research. Epigenetic clocks provide a measurable biological age estimate that correlates with mortality risk and responds to lifestyle interventions.
The canonical framework describing twelve cellular and molecular hallmarks of aging, foundational reading for longevity science.
Reviews the development and validation of epigenetic aging clocks including GrimAge and PhenoAge.
Covers the preclinical and early clinical evidence for compounds targeting cellular senescence accumulation.
Population-level evidence for whether healthspan compression is achievable through lifestyle intervention.
Personalized glycemic response research (notably the Weizmann Institute 2015 study) established that identical foods produce dramatically different postprandial glucose responses between individuals, driven largely by gut microbiome composition. Nutrigenetic variants, including MTHFR, FADS1/2, VDR, and BCMO1, create meaningful individual differences in nutrient requirements. Dietary pattern research consistently supports anti-inflammatory, whole-food-based approaches as population-level foundations for individual customization.
Landmark study demonstrating that gut microbiome composition predicts individual glycemic response to identical foods better than standard glycemic index.
Key study establishing the functional significance of FADS variants for omega-3 fatty acid conversion efficiency.
Reviews the molecular biology of VDR variants and vitamin D signaling in disease context.
Landmark RCT establishing Mediterranean dietary pattern benefits on cardiovascular events.
Insulin resistance, visceral adiposity, and metabolic inflexibility are interconnected drivers of cardiometabolic disease. Body composition, particularly the distinction between fat and lean mass, is a more physiologically informative health metric than body weight or BMI. Genetic contribution to obesity risk is substantial (40–70% heritability) and operates primarily through appetite regulation and metabolic rate pathways. Gene-environment interactions mean that lifestyle factors, especially physical activity, can substantially modify genetic obesity risk expression.
Reviews the concept of metabolic flexibility and its relationship to insulin resistance and cardiometabolic outcomes.
Demonstrates that regular physical activity substantially attenuates FTO-associated obesity risk, a key example of gene-environment interaction.
Documents why fat distribution (visceral vs subcutaneous) is more clinically relevant than total fat mass or BMI.
Evidence for ApoB measurement as a superior predictor of cardiovascular event risk.
GLP-1 receptor agonists represent the most significant pharmaceutical advance in obesity medicine in decades. Clinical trials demonstrate average weight losses of 15–22% of body weight, unprecedented for non-surgical interventions. Cardiovascular outcome trials show significant MACE reductions in high-risk populations. Emerging pharmacogenomics research is identifying genetic predictors of differential response, supporting the future of precision obesity medicine.
Pivotal trial demonstrating ~15% average weight loss with semaglutide 2.4mg vs placebo, establishing the new standard for pharmacological obesity treatment.
Demonstrated up to 22.5% average weight loss with tirzepatide, the largest weight reduction in any obesity pharmacotherapy trial.
Landmark trial showing 20% reduction in MACE with semaglutide in non-diabetic obesity population, establishing the cardiovascular indication.
Reviews body composition data from GLP-1 trials showing significant lean mass as a component of total weight loss.
Sleep is foundational to metabolic health, cognitive function, immune competence, and tissue repair. Even single nights of inadequate sleep measurably impair insulin sensitivity, inflammatory markers, and cognitive performance. Circadian biology, the timing of biological processes relative to the light-dark cycle, is a key determinant of metabolic and immune outcomes, independent of sleep duration. Recovery optimization encompasses sleep quality, circadian alignment, and strategic management of physiological stress.
Comprehensive review of bidirectional relationships between sleep quality/quantity and metabolic health.
Reviews molecular mechanisms of circadian biology and their relationship to metabolic regulation and disease risk.
Documents that a single night of partial sleep deprivation produces measurable insulin resistance in healthy participants.
Evidence-based supplement research consistently shows the largest benefits in populations with established deficiency or depletion. Magnesium, vitamin D, omega-3 fatty acids, CoQ10, and creatine have the most robust data for wellness and aging applications among widely used supplements. NAD+ precursors and GlyNAC show promising early-phase human data for aging markers. Personalization of supplement selection, form, and dose through nutrigenetic profiling and biomarker monitoring represents the next level of evidence-based precision supplementation.
Meta-analysis confirming inverse relationship between dietary magnesium and type 2 diabetes risk across multiple cohort studies.
Establishes that creatine + resistance training produces meaningfully greater gains in muscle mass and strength in older adults than training alone.
25% reduction in cardiovascular events with high-dose icosapentaenoic acid in statin-treated high-risk patients.
Randomized trial showing reduced cardiovascular events and mortality with CoQ10 supplementation in heart failure patients.
Pilot trial showing improvements in multiple aging markers with glycine + NAC (GlyNAC) supplementation in older adults.
About This Library
References in this library are educational summaries of peer-reviewed publications. Each paper title links to its canonical DOI record so readers can verify the citation and review the publisher's abstract or available full text. Databases such as PubMed, Cochrane Library, and Google Scholar provide additional clinical research search capability. All content here is for educational purposes and does not constitute medical advice.